Journal of Translational Medicine (Nov 2023)

Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages

  • Zhen Shen,
  • Xiyu Liu,
  • Guixiang Fan,
  • Jintong Na,
  • Qiaoqiao Liu,
  • Faquan Lin,
  • Zhikun Zhang,
  • Liping Zhong

DOI
https://doi.org/10.1186/s12967-023-04709-z
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Oncolytic viruses (OVs) for cancer treatment are in a rapid stage of development, and the direct tumor lysis and activation of a comprehensive host immune response are irreplaceable advantages of cancer immunotherapy. However, excessive antiviral immune responses also restrict the spread of OVs in vivo and the infection of tumor cells. Macrophages are functionally diverse innate immune cells that phagocytose tumor cells and present antigens to activate the immune response, while also limiting the delivery of OVs to tumors. Studies have shown that the functional propensity of macrophages between OVs and tumor cells affects the overall therapeutic effect of oncolytic virotherapy. How to effectively avoid the restrictive effect of macrophages on OVs and reshape the function of tumor-associated macrophages in oncolytic virotherapy is an important challenge we are now facing. Here, we review and summarize the complex dual role of macrophages in oncolytic virotherapy, highlighting how the functional characteristics of macrophage plasticity can be utilized to cooperate with OVs to enhance anti-tumor effects, as well as highlighting the importance of designing and optimizing delivery modalities for OVs in the future.

Keywords